
Standard Chem & Pharm Co Ltd
TWSE:1720

Standard Chem & Pharm Co Ltd
Revenue
Standard Chem & Pharm Co Ltd
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
![]() |
Standard Chem & Pharm Co Ltd
TWSE:1720
|
Revenue
NT$6.7B
|
CAGR 3-Years
14%
|
CAGR 5-Years
11%
|
CAGR 10-Years
8%
|
|
Y
|
YungShin Global Holding Corp
TWSE:3705
|
Revenue
NT$7.8B
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
3%
|
|
![]() |
Formosa Laboratories Inc
TWSE:4746
|
Revenue
NT$4.6B
|
CAGR 3-Years
14%
|
CAGR 5-Years
11%
|
CAGR 10-Years
5%
|
|
![]() |
ScinoPharm Taiwan Ltd
TWSE:1789
|
Revenue
NT$3.5B
|
CAGR 3-Years
6%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-3%
|
|
S
|
SCI Pharmtech Inc
TWSE:4119
|
Revenue
NT$1.4B
|
CAGR 3-Years
5%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
0%
|
|
![]() |
Lotus Pharmaceutical Co Ltd
TWSE:1795
|
Revenue
NT$17.6B
|
CAGR 3-Years
11%
|
CAGR 5-Years
17%
|
CAGR 10-Years
23%
|
Standard Chem & Pharm Co Ltd
Glance View
Standard Chemical & Pharmaceutical Co., Ltd. engages in the manufacture and sale of Chinese and western medicine, medicine raw materials, and health food. The company is headquartered in Tainan, Tainan. The Company’s products cover drugs for circulation systems, digest systems, respiratory systems, nervous systems and other diseases. Through its subsidiaries, the Company is also engaged in the sales of medical equipment, animal medicine, milk powder, cosmetics and others. The firm distributes its products both in domestic markets and overseas markets.

See Also
What is Standard Chem & Pharm Co Ltd's Revenue?
Revenue
6.7B
TWD
Based on the financial report for Sep 30, 2024, Standard Chem & Pharm Co Ltd's Revenue amounts to 6.7B TWD.
What is Standard Chem & Pharm Co Ltd's Revenue growth rate?
Revenue CAGR 10Y
8%
Over the last year, the Revenue growth was 8%. The average annual Revenue growth rates for Standard Chem & Pharm Co Ltd have been 14% over the past three years , 11% over the past five years , and 8% over the past ten years .